Pharmacogenomics

Abstract

The ongoing development in new genotyping methods necessitates an understanding of their potential benefits and limits in terms of pharmacogenomics utility. We give an overview of technologies that can be used in pharmacogenomics research and clinical practice in this chapter. The Human Genome Project’s completion has paved the way for the development of clinical instruments for patient evaluation. Pharmacogenomics may enable the identification of patients who are most likely to benefit from a specific drug, as well as those for whom the expense and risk are greater than the advantages. Both drug therapy’s safety and efficacy may improve. In the future, genotyping may be used to tailor drug treatment for large groups of individuals, lowering drug treatment costs and improving therapeutic efficacy and overall health.

Keywords: Clinical Pharmacogenetics Implementation Consortium (CPIC), Dutch Pharmacogenetics Working Group (DPWG, Pharmacogenomics (PGx), PharmGKB, US Food and Drug Administration (FDA).

Cite as